Equities research analysts forecast that Adamis Pharmaceuticals Corp (NASDAQ:ADMP) will announce earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Adamis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.14). Adamis Pharmaceuticals posted earnings of ($0.19) per share in the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The firm is expected to report its next earnings report on Monday, August 13th.
According to Zacks, analysts expect that Adamis Pharmaceuticals will report full-year earnings of ($0.74) per share for the current year, with EPS estimates ranging from ($0.82) to ($0.58). For the next financial year, analysts forecast that the firm will report earnings of ($0.45) per share, with EPS estimates ranging from ($0.68) to ($0.08). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Adamis Pharmaceuticals.
Adamis Pharmaceuticals (NASDAQ:ADMP) last announced its earnings results on Thursday, May 10th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The firm had revenue of $3.18 million during the quarter, compared to analyst estimates of $3.34 million. Adamis Pharmaceuticals had a negative net margin of 207.24% and a negative return on equity of 71.68%.
A number of brokerages recently issued reports on ADMP. B. Riley reissued a “buy” rating on shares of Adamis Pharmaceuticals in a research report on Wednesday, March 14th. Maxim Group set a $5.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 19th. ValuEngine raised Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. HC Wainwright set a $7.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 14th. Finally, Raymond James set a $7.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.88.
Shares of Adamis Pharmaceuticals traded up $0.10, reaching $4.15, during trading hours on Wednesday, according to Marketbeat. The stock had a trading volume of 282,593 shares, compared to its average volume of 623,727. The stock has a market cap of $136.06 million, a PE ratio of -4.61 and a beta of 0.28. The company has a quick ratio of 1.57, a current ratio of 1.88 and a debt-to-equity ratio of 0.07. Adamis Pharmaceuticals has a fifty-two week low of $2.35 and a fifty-two week high of $6.45.
A number of institutional investors and hedge funds have recently bought and sold shares of ADMP. Wells Fargo & Company MN raised its stake in Adamis Pharmaceuticals by 1,050.3% during the 4th quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after acquiring an additional 25,732 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Adamis Pharmaceuticals during the 1st quarter valued at approximately $244,000. Virtu Financial LLC purchased a new stake in Adamis Pharmaceuticals during the 4th quarter valued at approximately $442,000. Northern Trust Corp raised its stake in Adamis Pharmaceuticals by 50.7% during the 1st quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock valued at $489,000 after acquiring an additional 46,924 shares during the last quarter. Finally, B. Riley Financial Inc. purchased a new stake in Adamis Pharmaceuticals during the 4th quarter valued at approximately $1,022,000. 10.38% of the stock is owned by hedge funds and other institutional investors.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.